Latest Insider Transactions at Acelyrin, Inc. (SLRN)
This section provides a real-time view of insider transactions for Acelyrin, Inc. (SLRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ACELYRIN, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ACELYRIN, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2024
|
Daniel J. Becker Director |
SELL
Open market or private sale
|
Direct |
1
-0.03%
|
$6
$6.86 P/Share
|
|
May 15
2024
|
Mina Kim Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,230
-8.46%
|
$40,920
$4.47 P/Share
|
|
May 15
2024
|
Melanie Gloria Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,298
-7.33%
|
$41,192
$4.47 P/Share
|
|
May 15
2024
|
Sanam Pangali CLO & Head of People |
SELL
Payment of exercise price or tax liability
|
Direct |
921
-1.23%
|
$3,684
$4.47 P/Share
|
|
Apr 01
2024
|
Shao Lee Lin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,961
-0.63%
|
$59,766
$6.63 P/Share
|
|
Feb 20
2024
|
Shao Lee Lin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,701
-0.98%
|
$109,907
$7.6 P/Share
|
|
Jan 02
2024
|
Shao Lee Lin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,691
-0.66%
|
$74,837
$7.41 P/Share
|
|
Oct 04
2023
|
Paul Peloso Chief Medical Officer |
BUY
Other acquisition or disposition
|
Indirect |
39,133
+50.0%
|
-
|
|
Oct 04
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
132,236
+21.35%
|
-
|
|
Oct 04
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
1,161,747
-100.0%
|
-
|
|
Oct 04
2023
|
Patrick Machado Director |
BUY
Other acquisition or disposition
|
Indirect |
14,675
+50.0%
|
-
|
|
Oct 04
2023
|
Gil M Labrucherie CFO and CBO |
BUY
Other acquisition or disposition
|
Indirect |
40,763
+50.0%
|
-
|
|
Aug 16
2023
|
Ronald Oyston Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,332
+49.82%
|
-
|
|
Aug 16
2023
|
Melanie Gloria Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,584
+50.0%
|
-
|
|
Aug 16
2023
|
Mina Kim Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
114,676
+48.93%
|
-
|
|
Aug 16
2023
|
Paul Peloso Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,511
+48.73%
|
-
|
|
Aug 16
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
842,400
+34.32%
|
-
|
|
May 09
2023
|
Westlake Bio Partners Fund Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,250,000
+11.32%
|
$22,500,000
$18.0 P/Share
|
|
May 09
2023
|
Westlake Bio Partners Fund Ii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
8,540,729
+50.0%
|
-
|
|
May 09
2023
|
Dawn Svoronos Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$270,000
$18.0 P/Share
|
|
May 09
2023
|
Beth C Seidenberg Director |
BUY
Open market or private purchase
|
Direct |
60,000
+50.0%
|
$1,080,000
$18.0 P/Share
|
|
May 09
2023
|
Beth C Seidenberg Director |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+11.32%
|
$22,500,000
$18.0 P/Share
|
|
May 09
2023
|
Beth C Seidenberg Director |
BUY
Conversion of derivative security
|
Indirect |
8,540,729
+50.0%
|
-
|
|
May 09
2023
|
Henry O Gosebruch Director |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$900,000
$18.0 P/Share
|
|
May 09
2023
|
Ronald Oyston Chief People Officer |
BUY
Open market or private purchase
|
Indirect |
26
+50.0%
|
$468
$18.0 P/Share
|
|
May 09
2023
|
Ronald Oyston Chief People Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$18,000
$18.0 P/Share
|
|
May 09
2023
|
Daniel J. Becker Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$54,000
$18.0 P/Share
|
|
May 09
2023
|
Mina Kim Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$90,000
$18.0 P/Share
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
1,742,719
+50.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
1,742,719
-100.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
337,179
-30.45%
|
$8,092,296
$24.69 P/Share
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,107,213
+50.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
1,107,213
-100.0%
|
-
|
|
May 09
2023
|
Shao Lee Lin Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
1,161,747
+50.0%
|
-
|
|
May 09
2023
|
Mardi Dier CFO and CBO |
BUY
Open market or private purchase
|
Indirect |
1,750
+50.0%
|
$31,500
$18.0 P/Share
|
|
May 09
2023
|
Mardi Dier CFO and CBO |
BUY
Open market or private purchase
|
Direct |
5,556
+50.0%
|
$100,008
$18.0 P/Share
|
|
May 09
2023
|
Paul Peloso Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+50.0%
|
$108,000
$18.0 P/Share
|
|
May 09
2023
|
Ayur Maya Capital Management Company, LP Director |
BUY
Conversion of derivative security
|
Indirect |
9,334,735
+50.0%
|
-
|